All In Biotech

Drug Trial Radar · NCT00992901

Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

Hormonal and Neural Control of Insulin Secretion Following Gastric Bypass Surgery

Last checked: Nov 19, 2026Latest source record: Sep 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Oct 2009

Primary completion

Aug 2026

Study completion Aug 2027

Sponsor

Sponsor type
Academic, hospital or other
First posted
Oct 9, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Other
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

RYGB (roux-en-y gastric bypass) has been reported to reverse type 2 diabetes (T2DM) immediately after surgery before any significant weight loss. In addition, a growing number of patients have been recognized with life-threatening hyperinsulinemic hypoglycemia several years following their surgery. While the mechanisms by which RYGB improves glucose metabolism or alters islet cell function in patients after RYGB are not understood, recent studies suggest that increased secretion of GI hormones, primarily glucagon-like peptide 1 (GLP-1), as well as alteration in neural activity may contribute to enhanced insulin secretion in general, and to a greater extent in patients with hypoglycemia. The proposed research is designed to address the role of RYGB on insulin secretion by evaluating the contribution of stimulatory factors (neural and GI hormone) on islet cell function and the islet cell responsiveness to the physiologic stimulatory factors, in RYGB patients with and without hypoglycemia and non-operated controls.

Conditions

  • Post Bariatricsurgery
  • Hypoglycemia

Interventions

  • Exendin-(9-39)Drug

    A physiological study to evaluate the role of GLP-1 signaling in glucose tolerance and insulin secretion

  • AtropineDrug

    A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism

  • GLP-1 and GIPDrug

    A physiological study to evaluate the beta-cell sensitivity to different doses of exogenous gut hormones

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Gut hormones and neural signaling contribution to insulin secretion rate and glucose toleranceTime frame: Each study of the protocol is conducted up to seven hours with data collected at intervals specific to the individual study procedure.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Texas Diabetes Institute - University Health System

    San Antonio, Texas · Recruiting

  • South Texas Veterans Health Care System

    San Antonio, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.